• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

    12/27/24 9:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PGEN alert in real time by email

    GERMANTOWN, Md., Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement. Precigen anticipates gross proceeds from the private placement of $79.0 million before deducting offering expenses. In addition, the investors will have rights to exercise warrants to purchase 52,666,669 shares of Precigen's common stock at an exercise price of $0.75 per share (Warrants). The offering is expected to close on or before December 30, 2024, subject to customary closing conditions.

    Precigen Logo (PRNewsfoto/Precigen, Inc.)

    The private placement was led by affiliates of Patient Capital Management, with participation from Bill Miller, Randal J. Kirk, executive chairman of the board of directors of Precigen, and certain other investors.

    The net proceeds of the offering shall be used for working capital and general corporate purposes. Based on its current operating assumptions, Precigen expects this financing, together with Precigen's cash on hand, will extend its cash runway well into 2026, beyond the anticipated commercial launch of PRGN-2012 in the second half of 2025, if approved.

    Dividends on the Preferred Stock will be paid annually in cash when, as and if declared by the board of directors of Precigen, except that for the first two years following the issue date of the Preferred Stock, such dividends will be paid in kind in the form of an increase to the liquidation preference of the Preferred Stock by the amount of such dividends, together with warrants to acquire a number of additional shares of common stock equal to 50% of the amount of such dividends divided by the exercise price, subject to shareholder approval (as defined in the securities purchase agreement).

    The Preferred Stock will be redeemable, in whole or in part, for cash at Precigen's option at any time on or after the issue date for an amount equal to the liquidation preference at such time, plus accumulated and unpaid dividends.

    The Preferred Stock will be convertible into Precigen's common stock at the option of the holders thereof at any time on or after the later of the six month anniversary of the issue date and the date on which Precigen has, among other things, obtained shareholder approval. The Warrants are exercisable for shares of Precigen's common stock at any time after such shareholder approval.

    The Preferred Stock is convertible into shares of Precigen's common stock at an initial conversion price of approximately $1.125, which is 150% of the exercise price of the warrants. The conversion price is subject to upward adjustment based on the valuation of the common stock from time to time.

    Additional information regarding the Preferred Stock and Warrants will be included in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission.

    The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended (the Securities Act), or any state's securities laws, and are being issued and sold in reliance on Section 4(a)(2) of the Securities Act. The securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.

    The Preferred Stock and Warrants were offered directly to the Investors without a placement agent, underwriter, broker or dealer.

    Precigen has agreed to grant the Investors certain registration rights with respect to the Preferred Stock, the common stock issuable upon conversion of the Preferred Stock and the common stock issuable upon exercise of the Warrants.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy the Preferred Stock, Warrants or Precigen's common stock, nor shall there be any sale of the Preferred Stock or Warrants in any state or jurisdiction in which such offer, solicitation or sale would be unlawful under the securities laws of any such state or jurisdiction.

    About Precigen

    Precigen (NASDAQ:PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies are designed to enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.

    Cautionary Statement Regarding Forward-Looking Statements

    Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon Precigen's current expectations and projections about future events, including the closing of the private placement, and the intended use of proceeds of the private placement, anticipated timing of commercialization of PRGN 2012 and expected cash runway. Various factors may cause differences between Precigen's expectations and actual results. These risks and uncertainties include, without limitation, risks and uncertainties related to satisfaction of customary closing conditions related to the private placement, as well as that we have broad discretion in the use of proceeds. There can be no assurance that Precigen will be able to complete the private placement on the anticipated terms, or at all. For further information on potential risks and uncertainties, and other important factors, any of which could cause Precigen's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Precigen's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

    Investor Contact:

    Steven M. Harasym

    Vice President, Investor Relations

    Tel: +1 (301) 556-9850

    [email protected] 

    Media Contacts:

    Donelle M. Gregory

    [email protected] 

    Glenn Silver

    Lazar-FINN Partners

    [email protected]

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-announces-79-0-million-private-placement-offering-of-convertible-preferred-stock-302339619.html

    SOURCE Precigen, Inc.

    Get the next $PGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PGEN

    DatePrice TargetRatingAnalyst
    3/22/2024Neutral → Underweight
    JP Morgan
    5/23/2023Neutral
    JP Morgan
    11/18/2022$7.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Tennant Phil

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      4/18/25 5:06:44 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Shah Rutul R

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      4/18/25 5:02:52 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Lehr Donald P.

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      4/18/25 5:02:35 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

      – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

      4/16/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

      –  Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 Aden

      7/23/24 8:01:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actym Therapeutics Appoints Thomas Smart as CEO

      BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

      4/24/24 9:00:00 AM ET
      $ANAB
      $PGEN
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

      – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

      4/16/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Reports Full Year 2024 Financial Results and Business Updates

      FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025Results from pivotal clinical study of PRGN-2012 were published in The Lancet Respiratory MedicinePRGN-2012 treatment demonstrated durable complete responses with median duration of response of two years, with some complete responders surgery-free beyond three years as of August 28, 2024 data cutoffCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launchCompany ended 2024 with $97.9 million in cash, cash equivalents, and investments, extending i

      3/19/25 4:05:00 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

      GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu

      3/13/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Precigen downgraded by JP Morgan

      JP Morgan downgraded Precigen from Neutral to Underweight

      3/22/24 7:52:12 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on Precigen

      JP Morgan initiated coverage of Precigen with a rating of Neutral

      5/23/23 7:32:58 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Precigen with a new price target

      Cantor Fitzgerald initiated coverage of Precigen with a rating of Overweight and set a new price target of $7.00

      11/18/22 7:56:19 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Precigen Inc.

      PRE 14A - PRECIGEN, INC. (0001356090) (Filer)

      5/6/25 4:15:29 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Precigen Inc.

      10-K/A - PRECIGEN, INC. (0001356090) (Filer)

      4/28/25 5:23:16 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Precigen Inc.

      10-K - PRECIGEN, INC. (0001356090) (Filer)

      3/19/25 4:30:08 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Financials

    Live finance-specific insights

    See more
    • Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

      GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu

      3/13/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

      GERMANTOWN, Md., Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement. Precigen anticipates gross proceeds from the private placement of $79.0 million before deducting offering expenses. In addition, the investors will have rights to exercise warrants to purchase 52,666,669 shares of Precigen's common stock at an exercise price of $0.75 per share (Warrants). The offering

      12/27/24 9:00:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

      GERMANTOWN, Md., Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2024 financial results and provide business updates on Wednesday, August 14, 2024. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357

      8/9/24 8:00:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Precigen Inc.

      SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

      8/13/24 4:05:10 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Precigen Inc. (Amendment)

      SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

      5/3/24 8:01:15 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Precigen Inc. (Amendment)

      SC 13G/A - PRECIGEN, INC. (0001356090) (Subject)

      2/27/24 1:48:40 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, IP Affairs Perez Jeffrey Thomas bought $50,000 worth of shares (58,823 units at $0.85), increasing direct ownership by 9% to 743,097 units (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      8/13/24 5:09:47 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kirk Randal J bought $19,999,999 worth of shares (23,529,411 units at $0.85) (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      8/13/24 4:15:11 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kirk Randal J bought $136,327 worth of shares (96,686 units at $1.41) (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      12/29/23 7:30:15 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care